SCHEMBL14722738

SCHEMBL14722738

Cc1nn(C2CCCCO2)c2cccc(C#N)c12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.40
RET P07949 3/20 0.38
CYP4F2 P78329 2/20 0.35
CYP4A11 Q02928 2/20 0.35
ATR Q13535 2/20 0.35
ALDH1A1 P00352 3/20 0.33
NPSR1 Q6W5P4 2/20 0.33
GRM2 Q14416 1/20 0.33
KDM4E B2RXH2 3/20 0.33
GLA P06280 2/20 0.33
HPGD P15428 2/20 0.33
MEN1 O00255 1/20 0.33
POLB P06746 1/20 0.33
HTT P42858 1/20 0.33
KMT2A Q03164 1/20 0.33
HIF1A Q16665 1/20 0.33
MAP3K5 Q99683 1/20 0.32
PDE1A P54750 1/20 0.32
PDE1B Q01064 1/20 0.32
PDE1C Q14123 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14723265 0.85 RET (0.36) RETCYP4F2CYP4A11ATRALDH1A1
SCHEMBL14722724 0.85 RET (0.36) RETCYP4F2CYP4A11ATRALDH1A1
Ammonia Solution, Strong SCHEMBL28811804 0.84 GAA (0.42) GAARETCYP4F2CYP4A11ATR
SCHEMBL30950290 0.82 CYP4F2 (0.41) GAARETCYP4F2CYP4A11MEN1
SCHEMBL30861031 0.82 GAA (0.44) GAARETCYP4F2CYP4A11ATR
SCHEMBL27227964 0.82 GAA (0.44) GAARETCYP4F2CYP4A11ATR
SCHEMBL14722631 0.82 RET (0.39) GAARETCYP4F2CYP4A11ATR
SCHEMBL31162561 0.81 RET (0.38) GAARETCYP4F2CYP4A11ATR
SCHEMBL31093784 0.81 GAA (0.42) GAARETCYP4F2CYP4A11ATR
SCHEMBL29950914 0.81 GAA (0.40) GAARETCYP4F2CYP4A11ATR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2748159-A1 SERINE/THREONINE PAK1 INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2014-07-02 EP disclosed
US-8637537-B2 Serine/threonine kinase inhibitors GENENTECH, INC. (US) 2014-01-28 US disclosed
US-20130225620-A1 SERINE/THREONINE KINASE INHIBITORS GENENTECH, INC. (US) 2013-08-29 US disclosed
WO-2013026914-A1 SERINE/THREONINE PAK1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2013-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225620-A1 SERINE/THREONINE KINASE INHIBITORS PAK1, AKT1, RB1 GAA 3564/4885RET 97/4885CYP4F2 4881/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.